- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Amarin Announces U.S. Patent Issuance for Vascepa (Icosapent Ethyl)
Omega 3 fatty acid reduces triglyceride levels (Nov. 27)
Amarin Corporation, based in Bedminster, N.J., announced on November 27 that the U.S. Patent and Trademark Office has issued a patent covering the company’s Vascepa (icosapent ethyl) capsules.
On September 4, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,318,715, has a term that expires no earlier than in 2030. Amarin plans to list this patent in the FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations, or Orange Book.
Amarin now has 10 U.S. patents either issued or allowed as well as more than 30 additional patent applications currently in prosecution in the U.S.
Vascepa is an omega 3 fatty acid comprising not less than 96% eicosapentaenoic acid (EPA). The product is indicated as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (≥ 500 mg/dL).